Comparing Kenvue (NYSE:KVUE) and Medifast (NYSE:MED)

Kenvue (NYSE:KVUE) and Medifast (NYSE:MED) are both consumer staples companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Earnings & Valuation

This table compares Kenvue and Medifast”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kenvue	$15.12 billion	2.48	$1.47 billion	$0.87	22.48
Medifast	$385.79 million	0.34	-$18.67 million	($2.33)	-5.09

Kenvue has higher revenue and earnings than Medifast. Medifast is trading at a lower price-to-earnings ratio than Kenvue, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

97.6% of Kenvue shares are held by institutional investors. Comparatively, 95.5% of Medifast shares are held by institutional investors. 1.6% of Kenvue shares are held by company insiders. Comparatively, 3.7% of Medifast shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and price targets for Kenvue and Medifast, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kenvue	0	10	0	0	2.00
Medifast	1	1	0	1	2.33

Kenvue currently has a consensus target price of $18.50, suggesting a potential downside of 5.40%. Medifast has a consensus target price of $12.00, suggesting a potential upside of 1.10%. Given Medifast’s stronger consensus rating and higher probable upside, analysts clearly believe Medifast is more favorable than Kenvue.

Profitability

This table compares Kenvue and Medifast’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kenvue	10.76%	21.22%	8.37%
Medifast	-8.08%	-6.69%	-5.25%

Volatility and Risk

Kenvue has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500. Comparatively, Medifast has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500.

Summary

Kenvue beats Medifast on 9 of the 14 factors compared between the two stocks.

About Kenvue

Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair, sun, and other care products under the Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX brand names. The Essential Health segment offers oral and baby, women's health, wound, and other care products under the Listerine, Johnson's, Band-Aid, and Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey.

About Medifast

Medifast, Inc., through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names. The company markets its products through point-of-sale transactions, as well as through ecommerce platform. Medifast, Inc. was founded in 1980 and is headquartered in Baltimore, Maryland.